Answers are grounded in this paper and cite their sources.
We appreciate the opportunity to respond to Kim et al,1Kim R.Y. Sears C.R. Pastis N.J. Liquid markers for risk stratification of pulmonary nodules, ready for prime time?: yes!.Chest Pulm. 2024; Abstract Full Text PDF Google Scholar supporting the use of liquid biomarkers for risk stratification of pulmonary nodules. To start, Kim et al are to be commended for their thoughtful argument. Both teams agree that liquid biomarkers have the potential to improve clinical decision-making. However, both papers also highlight current limitations in biomarker use. Notably, candidate biomarkers are in the preclinical or clinical validation stages of development (Fig 1). Indeed, these limitations underscore our view that there is currently insufficient evidence to support the routine use of biomarkers for nodule management in clinical practice.1Kim R.Y. Sears C.R. Pastis N.J. Liquid markers for risk stratification of pulmonary nodules, ready for prime time?: yes!.Chest Pulm. 2024; Abstract Full Text PDF Google Scholar,2Nadig T.R. Smyth R. Bade B.C. Liquid markers for risk stratification of pulmonary nodules, ready for prime time?: not yet.Chest Pulm. 2024; Abstract Full Text PDF Google Scholar It is noteworthy that both groups cite the same literature, but differ on the interpretation of the findings. Therefore, we wish to highlight two points in our response. First, signals of potential clinical benefit should not be equated with readiness for widespread clinical use. Optimism from early data must be balanced against possible harm from premature implementation. The example of hydroxychloroquine as a therapy for COVID-19 comes to mind.3Horby P. Mafham M. et al.RECOVERY Collaborative GroupEffect of hydroxychloroquine in hospitalized patients with Covid-19.N Engl J Med. 2020; 383: 2030-2040Crossref PubMed Scopus (845) Google Scholar In the setting of an urgent need and without viable alternatives or guidelines, hydroxychloroquine was widely used. With subsequent studies showing no clinical benefit from hydroxychloroquine in COVID-19, there was clearly potential for unintended risk without benefit. Similarly, if pulmonologists endorse widespread use of biomarkers for lung nodule assessment without sufficient evaluation, the risk of worsened outcomes (eg, delayed cancer diagnoses, invasive procedures for benign conditions) may also be increased. We again highlight the work by Tanner et al,4Tanner N.T. Brasher P.B. Jett J. Silvestri G.A. Effect of a rule-in biomarker test on pulmonary nodule management: a survey of pulmonologists and thoracic surgeons.Clin Lung Cancer. 2020; 21: e89-e98Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar suggesting that without proper education, biomarker implementation may not have the intended effect. Second, in our zeal to reduce the number of invasive procedures (and associated complications) during lung nodule evaluation, we should not circumvent established processes for biomarker decision-making. As outlined by our colleagues, a clinical utility study5NCT04171492Google Scholar and a clinical validation study6NCT05306288Google Scholar are currently underway. Because many liquid biomarkers have undergone testing, yet few have reached clinical utility testing, the distance between may help and does help can be wide. Put another way, we cannot tailor the definition of readiness. Policy statements are painstakingly developed using a rigorous process to ensure recommendations are valid and reliable. This approach is essential in promoting transparency, consistency, and (ultimately) widespread implementation of the best test.7Mazzone P.J. Sears C.R. Arenberg D.A. et al.Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American Thoracic Society policy statement.Am J Respir Crit Care Med. 2017; 196: e15-e29Crossref PubMed Scopus (88) Google Scholar Therefore, we reiterate that the criterion standard benchmarks established by the lung cancer community (and outlined in the American Thoracic Society policy statement) must be met.7Mazzone P.J. Sears C.R. Arenberg D.A. et al.Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American Thoracic Society policy statement.Am J Respir Crit Care Med. 2017; 196: e15-e29Crossref PubMed Scopus (88) Google Scholar, 8Silvestri G.A. Tanner N.T. Kearney P. et al.Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial.Chest. 2018; 154: 491-500Abstract Full Text Full Text PDF PubMed Scopus (107) Google Scholar, 9Gaga M. Chorostowska-Wynimko J. Horváth I. et al.Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals.Eur Respir J. 2021; 572002682Crossref PubMed Scopus (20) Google Scholar, 10Mathios D. Johansen J.S. Cristiano S. et al.Detection and characterization of lung cancer using cell-free DNA fragmentomes.Nat Commun. 2021; 12: 5060Crossref PubMed Scopus (169) Google Scholar Pulmonologists should insist on serum biomarkers completing their current clinical utility testing and attaining the standards required for a clinically effective biomarker: (1) improving clinical decision-making, (2) reducing unnecessary procedures, and (3) lowering lung cancer mortality. Only then should liquid biomarkers be incorporated into guideline-based clinical care (prime time). In summary, we agree with Kim et al that preliminary data are exciting, and we are closer than ever to the inclusion of liquid biomarkers in lung nodule assessment. However, for the safety of the patients, it is incumbent on pulmonologists to await the results of ongoing trials to ensure these novel diagnostic approaches are indeed ready for prime time. This study was supported by an investigator-initiated research grant from the American Cancer Society and investigator-initiated research support from the VA Central Office.
No takes yet. Share an insight, caveat, or question.
Nadig et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: